An interventional study of Low AGE diet and Research blood draw in Breast Cancer, sponsored by Washington University School of Medicine. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-08.
Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Treatment
The scientific premise for this study is the known impact of overweight/obesity on breast cancer risk and outcomes, the association between advanced glycation end-products (AGE) and high fat, highly processed foods common in Western diets, and the preclinical evidence suggesting a link between AGE and breast cancer independent of weight. The association between dietary and serum AGE in breast cancer survivors and prognosis has not been previously evaluated. However, preclinical studies suggest that AGE may represent a novel, lifestyle-linked, modifiable, prognostic biomarker, which could be targeted through lifestyle (diet and exercise) and/or pharmaceutical interventions to improve breast cancer prognosis. The proposed study will pave the way for a large scale randomized controlled trial to evaluate the impact of a low AGE diet on weight (BMI), known (IL-6 and CRP) and novel (AGE and RAGE) prognostic biomarkers, and ultimately on breast cancer prognosis.
12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.
This study's enrollment of 14 is below the median of 72 across 9,303 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Washington University School of Medicine is the lead sponsor of 1,765 studies on the registry; 271 are open to participants now.
Of its 324 completed or terminated interventional studies of FDA-regulated products, 212 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
* Patients will complete a food frequency questionnaire, \& if found to have a high AGE diet at baseline, will then begin the study the 24-week low AGE dietary intervention. Patients will complete a 3 day food record prior to receiving remotely delivered education on AGEs on how to adhere to a low AGE diet by the study dieticians prior to starting. This session will provide education on dietary AGE \& how to prepare \& choose low AGE meals * Subsequent sessions with the dieticians will be conducted remotely \& will be 30-60 minutes in duration, with the exception of sessions scheduled for weeks when a study blood draw is required, when visits with the dietician may occur in person. These sessions will occur at the following schedule: weekly during the first 2 months (8 sessions), every other week during the next 2 months (4 sessions, aka step down sessions), monthly for the remaining 2 months (2 sessions) * 3 day food records will be collected at 12 \& 24 weeks, in addition to baseline.
Other: Low AGE diet · Procedure: Research blood draw
The recommended daily AGE intake will be either: * 7,500 kilounits \[ku\], which is a 50% reduction from the average 15,000 ku consumed by most adults or * a 50% reduction from their baseline AGE intake (based on 3-day food AGE record)
Baseline (Week 0), Week 4, Week 12, and Week 24 (end of intervention)
Feasibility as measured by adherence rate
* Feasibility is a defined adherence rate of at least 80% of participants enrolled * Diet adherence will be categorized by the study dietitian at the end of the study and before the results of AGEs in serum or any analysis of outcomes to avoid bias. Following each phone session with the participants, the dietitian will elicit answers to the following question: since the last call did the participant use any cooking methods they were advised to avoid for certain food items? (yes/no). * The information will be used to calculate an adherence score. Adherence score is % phone calls of patient's report for full maintaining instructions to reduce AGEs. * Very high adherence= ≥80%; good adherence= 60-80%; partial adherence= 40-60%; lack of adherence but intention to adhere more in the future= ≤40%; lack of adherence and no intention to adhere more= ≤40%
Time frame: At study completion for all enrolled participants (estimated to be 15 months)
Feasibility as measured by dropout rate
-Feasibility is defined as a dropout rate of less than 20% of participants enrolled
Time frame: At study completion for all enrolled participants (estimated to be 15 months)
Change in dietary AGE
-Dietary AGE is estimated based on analysis of the 3 day food record patients will complete at baseline and study completion. A specific dietary AGE value will be assigned to each item on the 3 day food recall by consultant and dietary AGE expert Jaime Uribarri, MD. This value is based on his published dietary AGE database which accounts for type of food, portion size and cooking methods.
Time frame: At baseline and study completion (24 weeks)
Change in serum AGE
* Blood specimens for serum AGE analysis will be shipped from the University of San Diego Biorepository to the Medical University of South Carolina to be analyzed in the lab of study team member and expert AGE analyst, Dr. David Turner. * AGE (measured by the AGE metabolite carboxymethyllysine (ug/ml)) will be assessed in serum using commercially available 96-well format ELISA's and ROS detection kits (Cell Biolabs). Nε-carboxymethyllysine (CML) is an AGE metabolite extensively studied in animal models of disease and with regard to food content.
Time frame: Baseline, week 12, and week 24
Correlation between serum AGE levels and BMI
-The relationship between serum AGE levels and BMI will be assessed using rank based correlation.
Time frame: Baseline, 12 weeks, and 24 weeks
Correlation between serum AGE levels and serum CRP
-The relationship between serum AGE levels and serum CRP will be assessed using rank based correlation.
Time frame: Baseline, 12 weeks, and 24 weeks
Correlation between serum AGE levels and IL6
-The relationship between serum AGE levels and IL6 will be assessed using rank based correlation.
Time frame: Baseline, 12 weeks, and 24 weeks
Correlation between serum AGE levels and glucose
-The relationship between serum AGE levels and glucose will be assessed using rank based correlation.
Time frame: Baseline, 12 weeks, and 24 weeks
Correlation between serum AGE levels and leptin
-The relationship between serum AGE levels and leptin will be assessed using rank based correlation.
Time frame: Baseline, 12 weeks, and 24 weeks
Correlation between serum AGE levels and adiponectin
-The relationship between serum AGE levels and adiponectin will be assessed using rank based correlation.
Time frame: Baseline, 12 weeks, and 24 weeks
Correlation between dietary AGE and BMI
-The relationship between dietary AGE and BMI will be assessed using rank based correlation.
Time frame: Baseline, 12 weeks, and 24 weeks
Correlation between dietary AGE and serum CRP
-The relationship between dietary AGE and serum CRP will be assessed using rank based correlation.
Time frame: Baseline, 12 weeks, and 24 weeks
Correlation between dietary AGE and IL6
-The relationship between dietary AGE and IL6 will be assessed using rank based correlation.
Time frame: Baseline, 12 weeks, and 24 weeks
Correlation between dietary AGE and insulin
-The relationship between dietary AGE and insulin will be assessed using rank based correlation.
Time frame: Baseline, 12 weeks, and 24 weeks
Correlation between dietary AGE and glucose
-The relationship between dietary AGE and glucose will be assessed using rank based correlation.
Time frame: Baseline, 12 weeks, and 24 weeks
Correlation between dietary AGE and leptin
-The relationship between dietary AGE and leptin will be assessed using rank based correlation.
Time frame: Baseline, 12 weeks, and 24 weeks
Correlation between dietary AGE and adiponectin
-The relationship between dietary AGE and adiponectin will be assessed using rank based correlation.
Time frame: Baseline, 12 weeks, and 24 weeks
Plan to share: Yes — All research data will be shared between Dr. Peterson and the study team will be available to all investigators named on this proposal. The primary investigators are also willing to share data and materials with other eligible investigators and collaborators through academically established means. Final data will be shared in an openly and timely manner while ensuring the privacy and confidentiality of participants through presentations at scientific seminars and conference and publications in peer reviewed journals. Information about the intervention protocol and survey tools will be made available to others upon request.
Supporting information: Study protocol, Sap
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Washington University School of Medicine